The risk-based approach has become one of the key elements of modern clinical research. Following the update of the international ICH GCP E6(R3) requirements, regulators increasingly assess not only procedural compliance but also an organization’s ability to identify, analyze, and control risks affecting participant safety and data reliability.
Today, risk-based quality management is regarded as a mandatory component of the quality system for sponsors, CROs, and investigative sites alike.
Modern inspections evaluate not only the presence of documentation, but also the maturity of the entire clinical trial quality management system.

What Are Considered Critical Risks in Clinical Trials?
The risk-based approach primarily focuses on critical processes that may impact:

• participant safety;
• patient rights;
• data reliability and integrity;
• protocol compliance;
• reliability of study outcomes.

Particular attention is given to:

• the informed consent process;
• adverse event reporting;
• source documentation;
• deviation management;
• electronic systems management;
• compliance with patient inclusion and exclusion criteria.

Regulators expect organizations to proactively identify critical-to-quality factors and document their approach to controlling them.
What Do Inspectors Review When Assessing a Risk-Based Approach?
Risk Assessment
During an inspection, inspectors may request:

• risk assessment documentation;
• risk matrices;
• descriptions of the assessment methodology;
• criteria for process criticality;
• risk management plans;
• results of periodic risk reviews.

Inspectors evaluate:

• whether the identified risks are genuinely study-specific;
• how priorities are established;
• which control measures have been implemented;
• whether risk assessments are updated throughout the study.

A purely formal approach without meaningful analysis is considered a serious weakness of the quality system.
Centralized Monitoring
Modern clinical trials increasingly rely on centralized monitoring instead of exclusively on-site monitoring.
Regulators review:

• trend analysis;
• quality signals;
• key risk indicators (KRIs);
• statistical data analysis;
• timeliness of issue escalation;
• detection of anomalies between study sites.

Particular attention is paid to how the organization:

• responds to quality signals;
• documents decisions;
• performs escalation activities.

Inspectors expect centralized monitoring to help identify issues before they affect patient safety or data integrity.
CAPA: Corrective and Preventive Actions
One of the most frequently inspected areas remains the CAPA (Corrective and Preventive Actions) system.
Regulators assess:

• timeliness of corrective actions;
• quality of root cause analysis;
• realism of the CAPA plan;
• tracking of implementation timelines;
• effectiveness of implemented actions;
• prevention of recurring deviations.

Deviation Management
Deviation management systems have become one of the key focus areas during modern inspections.
Inspectors review:

• deviation classification;
• assessment of impact on safety and data;
• timeliness of investigations;
• documentation of decisions;
• recurrence of issues;
• escalation systems.

Regulators expect organizations to identify systemic issues rather than treating each deviation in isolation.
Quality System Assessment
The risk-based approach is closely linked to the overall quality management system.
During inspections, regulators assess:

• risk management;
• training systems;
• internal audits;
• contractor oversight;
• vendor management;
• inspection readiness.

Inspectors increasingly evaluate the maturity of the organization’s quality culture, not merely documentation compliance.
How to Prepare for an Inspection of a Risk-Based Approach?
To reduce regulatory risks, organizations are advised to:
1. Regularly Update Risk Assessments
Risk assessments should be reviewed throughout the entire study lifecycle.
2. Implement Comprehensive Centralized Monitoring
It is important to use:

• trend analysis;
• quality metrics;
• process improvement pathways.

3. Strengthen Root Cause Analysis
Superficial root cause analysis is one of the most common findings during inspections.
4. Monitor CAPA Effectiveness
CAPA activities should not only be formally closed but should demonstrably reduce the risk of recurrence.
5. Develop a Quality Culture
Employees should understand:

• which processes are critical;
• what risks exist;
• how to identify quality signals;
• how to escalate issues in a timely manner.

FAQ
What Is a Risk-Based Approach in Clinical Trials?
It is a quality management system in which an organization focuses on identifying and controlling critical risks that affect participant safety and data reliability.
What Is RBQM?
RBQM (Risk-Based Quality Management) is a risk-based quality management approach built on continuous risk assessment and control of critical study processes.
What Is KRI?
KRI (Key Risk Indicators) are metrics used to identify potential issues within a clinical study.
Conclusion
The risk-based approach is becoming a mandatory element of modern quality systems in clinical research. Regulators expect organizations not merely to comply formally with procedures, but to actively manage risks, identify issues in a timely manner, and continuously improve processes.